Daniel E. Geffken

2021 - Sevion Therapeutics

In 2021, Daniel E. Geffken earned a total compensation of $130.8K as Interim Chief Financial Officer at Sevion Therapeutics.

Compensation breakdown

Other$130,750
Total$130,750

Geffken received $130.8K in other compensation, accounting for 100% of the total pay in 2021.

Rankings

In 2021, Daniel E. Geffken's compensation ranked 12,191st out of 12,415 executives tracked by ExecPay. In other words, Geffken earned more than 1.8% of executives.

ClassificationRankingPercentile
All
12,191
out of 12,415
2nd
Division
Manufacturing
5,399
out of 5,501
2nd
Major group
Chemicals And Allied Products
2,339
out of 2,371
1st
Industry group
Drugs
2,064
out of 2,092
1st
Industry
Biological Products, Except Diagnostic Substances
443
out of 449
1st
Source: SEC filing on April 28, 2023.

Geffken's colleagues

We found two more compensation records of executives who worked with Daniel E. Geffken at Sevion Therapeutics in 2021.

2021

Sumit Aggarwal

Sevion Therapeutics

Chief Executive Officer

2021

Vijay Modur

Sevion Therapeutics

Head of Research and Development

News

You may also like